Skip to content

Amifampridine

Potassium Channel Blocker — NERVOUS SYSTEM

Also known as: 3,4-DAP, amifampridin, amifampridine phosphate, DAP, firdapse

OfpEMA approvedFDA approvedOrphan designationATC N07XX05

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Amifampridine is an ofp drug in the Potassium Channel Blocker class catalogued in DrugCentral. It was first approved by the EMA in 2009. Its mechanism of action is classified as Potassium Channel Antagonists. DrugCentral lists 1 molecular target, including KCNQ3|KCNQ2|KCNH1|KCNA2|KCNA6|KCNA3|KCNA4|KCNA5|KCNC1|KCNQ1|KCNQ4|KCNC4|KCNA1|KCNH2|KCNC3|KCNB1|KCNA10|KCNV1|KCNH5|KCNG3|KCNG4|KCNV2|KCNB2|KCNS1|KCNH8|KCNC2|KCNA7|KCNS3|KCNH6|KCNF1|KCNQ5|KCNH7|KCND1|KCND2|KCNG1|KCNG2|KCND3|KCNH3|KCNS2|KCNH4. Recorded indications include Eaton-Lambert syndrome.

  • Approval status: ofp (first approved 2009 by the EMA).
  • Drug class: Potassium Channel Blocker.
  • Mechanism of action: Potassium Channel Antagonists.
  • Molecular targets: KCNQ3|KCNQ2|KCNH1|KCNA2|KCNA6|KCNA3|KCNA4|KCNA5|KCNC1|KCNQ1|KCNQ4|KCNC4|KCNA1|KCNH2|KCNC3|KCNB1|KCNA10|KCNV1|KCNH5|KCNG3|KCNG4|KCNV2|KCNB2|KCNS1|KCNH8|KCNC2|KCNA7|KCNS3|KCNH6|KCNF1|KCNQ5|KCNH7|KCND1|KCND2|KCNG1|KCNG2|KCND3|KCNH3|KCNS2|KCNH4 (1 listed in DrugCentral).
  • Indications: Eaton-Lambert syndrome.
  • ATC code: N07XX05 (Other nervous system drugs).
  • Molecular formula: C5H7N3; molecular weight 109.13 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Eaton-Lambert syndrome

Mechanism & targets

Mechanism of action (MoA)Potassium Channel Antagonists
Established pharmacologic classPotassium Channel Blocker

Molecular targets (1)

TargetGeneActionActivity
Voltage-gated potassium channelKCNQ3|KCNQ2|KCNH1|KCNA2|KCNA6|KCNA3|KCNA4|KCNA5|KCNC1|KCNQ1|KCNQ4|KCNC4|KCNA1|KCNH2|KCNC3|KCNB1|KCNA10|KCNV1|KCNH5|KCNG3|KCNG4|KCNV2|KCNB2|KCNS1|KCNH8|KCNC2|KCNA7|KCNS3|KCNH6|KCNF1|KCNQ5|KCNH7|KCND1|KCND2|KCNG1|KCNG2|KCND3|KCNH3|KCNS2|KCNH4blocker—

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2018-11-28FDA—CATALYST PHARMSYes
2009-12-23EMA—BioMarin Europe LtdYes

ATC classification

ATC codeTherapeutic hierarchy
N07XX05NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › OTHER NERVOUS SYSTEM DRUGS › Other nervous system drugs

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

  • EMA label
  • FDA label: NAT2 · Actionable PGx
  • HCSC label: NAT2 · Actionable PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Myasthenia gravis crisis42.1
Asthenia34.4
Paraesthesia oral31.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Amifampridine is on its molecule page.

Molecular formulaC5H7N3
Molecular weight109.13 g/mol
CAS number54-96-6
InChIKeyOYTKINVCDFNREN-UHFFFAOYSA-N
PubChem CID5918
NC1=CC=NC=C1N

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Amifampridine used for?

DrugCentral lists the following indications for Amifampridine: Eaton-Lambert syndrome.

How does Amifampridine work?

Amifampridine is classified as Potassium Channel Antagonists; its molecular targets in DrugCentral include KCNQ3|KCNQ2|KCNH1|KCNA2|KCNA6|KCNA3|KCNA4|KCNA5|KCNC1|KCNQ1|KCNQ4|KCNC4|KCNA1|KCNH2|KCNC3|KCNB1|KCNA10|KCNV1|KCNH5|KCNG3|KCNG4|KCNV2|KCNB2|KCNS1|KCNH8|KCNC2|KCNA7|KCNS3|KCNH6|KCNF1|KCNQ5|KCNH7|KCND1|KCND2|KCNG1|KCNG2|KCND3|KCNH3|KCNS2|KCNH4 (blocker).

When was Amifampridine first approved?

Amifampridine was first approved by the EMA in 2009.

What drug class does Amifampridine belong to?

Amifampridine is in the Potassium Channel Blocker class.

What is the chemical formula of Amifampridine?

Amifampridine has the molecular formula C5H7N3 and a molecular weight of 109.13 g/mol.

Browse: all drugs starting with A · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval2009-12-23
AgencyEMA
Targets1
Indications1
FormulaC5H7N3
DrugCentral ID4336
Interactive profile